The impact of multiple low-level BCR-ABL1 mutations on response to ponatinibWendy T Parker, Susan Branford, Bronte A. Jamison et al.|Blood|2016Cited by 65
Efficacy and Safety of Duvelisib Following Disease Progression on Ofatumumab in Patients with Relapsed/Refractory CLL or SLL in the DUO Crossover Extension StudyMatthew S. Davids, Ulrich Jäger, Bryone J. Kuss et al.|Clinical Cancer Research|2020Cited by 43